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Abstract
Background:  The  NUP98 gene is involved in multiple rearrangements in haematological
malignancy. The leukemic cells in an acute myeloid leukemia (AML) patient with a t(9;11)(p22;p15)
were recently shown to have a fusion between the NUP98 gene and the LEDGF gene but it was not
demonstrated that this fusion was recurrent in other leukaemia patients with the same
translocation.
Results: We used RT-PCR to analyse the leukemic cells from an AML patient who presented with
a cytogenetically identical translocation as the sole chromosomal abnormality. A NUP98-LEDGF
fusion transcript was observed and confirmed by sequencing. The reciprocal transcript was also
observed. The fusion transcript was not detectable during remission and recurred at relapse. The
breakpoints in the NUP98 and LEDGF genes were different to those previously reported. The
NUP98 breakpoint occurs in the intron between exons 8 and 9. It is the most 5' breakpoint
reported in a translocation involving the NUP98 gene. All of the LEDGF gene is included in the fusion
except for exon 1 which codes for the first 24 amino terminal amino acids.
Conclusions: Our results show that fusion of the NUP98 and LEDGF genes is a new recurrent
translocation in AML.
Background
The translocation, t(9;11)(p22;p15), was first reported in
a patient with AML M1 [1]. Recently, a second AML M1
patient with a cytogenetically identical translocation was
shown to have a fusion transcript between the 5' end of
the NUP98 gene on 11p15 and the 3' end of the LEDGF
gene on 9p22 [2].
We have identified a third AML patient with a cytogenet-
ically identical translocation. The patient, a 60 year old
Caucasian woman presented with a white cell count of
1.5 x 109/L due to neutropenia. The bone marrow
showed 50% blasts and 30% promyelocytes. She was di-
agnosed as AML M2. Cytogenetics showed
46,XX,t(9;11)(p22;p15) [13 cells]/46,XX [2 cells]. Induc-
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tion chemotherapy with ARA-C, idarubicin and etopo-
side was abandoned after the patient developed a severe
neutropenic reaction at the end of the first course. Nev-
ertheless, complete haematological and cytogenetic re-
mission was obtained. After 54 months, the patient
relapsed with frank leukemia and a white cell count of 50
x 109/L. Due to the patient's wishes, only supportive
therapy was given, and she died of her disease a few days
later with a rapidly escalating blast cell burden. Cytoge-
netics of the relapse peripheral blood showed the same
karyotype as at presentation 46,XX,t(9;11)(p22;p15) [19
cells]/46,XX [3 cells].
We analysed the leukemic cells from this patient in order
to determine whether the fusion of NUP98 and LEDGF
as a result of the t(9;11)(p22;p15) is a recurrent event in
AML.
Results and discussion
The NUP98 gene is known to be involved in multiple re-
arrangements in haematological malignancy [3–10]. The
11p15 breakpoint in our patient suggested possible dis-
ruption of the NUP98 gene. We therefore attempted a
3'RACE approach to test for the presence of a fusion
mRNA using a method similar to that used to identify
RAP1GDS1 as a fusion partner of NUP98 [9]. As the most
5' break in NUP98 known at the time occurred in the in-
tron after exon 10 [9], we used a NUP98 forward primer
from exon 9 for 3'RACE. This approach resulted in a
number of RT-PCR products from the t(9;11) patient that
were different in size from the NUP98 3'RACE products
amplified from normal individuals. However sequence
analysis of these products showed that they resulted
from partially spliced NUP98 mRNAs rather than novel
fusion mRNAs (results not shown).
Subsequently, an AML patient was reported in which the
t(9;11)(p22;p15) resulted in an in-frame fusion of the
NUP98 and LEDGF genes [2]. This involved fusion of
NUP98 exon 9 to LEDGF exon 6. As RACE of our patient
had failed to detect any fusions including exon 9 of
NUP98, we used a NUP98 primer from exon 8 with a
LEDGF reverse primer from exon 6 for RT-PCR (Figure
1). An RT-PCR product was obtained in which exon 8 of
NUP98 was fused in-frame to exon 2 of LEDGF. The
NUP98 breakpoint thus maps to the 5.5 kb intron be-
tween exons 8 and 9 and is the most 5' NUP98 break-
point reported to date. The LEDGF breakpoint in our
patient is more 5' than that found in the patient reported
by Ahuja et al [2] and occurs within the 3.5 kb intron be-
tween exons 1 and 2.
We also used RT-PCR to assess expression of the
NUP98-LEDGF fusion mRNA in remission peripheral
blood taken twenty months after presentation. Using
standard PCR conditions with 35 cycles of PCR (Figure
1), there was no fusion transcript visible. Even after first
round PCR with 45 cycles followed by fully nested PCR
with 45 cycles we did not detect NUP98-LEDGF fusion
mRNA in the remission sample (data not shown). How-
ever, RT-PCR of the relapse specimen showed that the
NUP98-LEDGF transcript was re-expressed consistent
with the association of the translocation with the disease.
We were able to amplify the reciprocal LEDGF-NUP98
fusion transcript at presentation and relapse. Sequenc-
ing of this product showed an in-frame fusion of exon 2
of LEDGF to exon 9 of NUP98 as expected. The recipro-
cal transcript is unlikely to be important in the pathogen-
esis of the disease as the previous report did not observe
a reciprocal fusion transcript [2]. However, it is possible
that the reciprocal fusion transcript may modulate the
course of the disease particularly in the light of the less
aggressive form of the disease seen in our patient. Simi-
lar patient to patient differences in whether or not the re-
ciprocal transcript is expressed have also been noted for
other fusions including BCR-ABL and NUP98-
RAP1GDS1[9,11].
We were also able to obtain RNA using fixed leukemic
cells from the first reported t(9;11) patient [1]. This RNA
Figure 1
RT-PCR analysis of NUP98-LEDGF expression. RT-
PCR for the NUP98-LEDGF fusion was performed as outlined
in the materials and methods. RNA samples are from periph-
eral blood mononuclear cells taken from a normal donor
(lane 1), bone marrow mononuclear cells taken from t(9;11)
patient presentation (lane 2), and peripheral blood mononu-
clear cells taken from t(9;11) patient remission (lane 3) and
relapse (lane 4). Lane 5 is a relapse specimen negative con-
trol RT-PCR without reverse transcriptase. M is pUC19/
HpaII molecular weight marker. The lower panel shows the
corresponding PBGD PCR control reactions.BMC Genetics 2001, 2:20 http://www.biomedcentral.com/1471-2156/2/20
was highly degraded and had an average length of 200
bases. Despite being able to amplify a 400 bp NUP98
RT-PCR product, we were unable to amplify a a smaller
product corresponding to either of the 2 known NUP98-
LEDGF fusions nor any of a number of other potential
NUP98-LEDGF fusions that we tried.
The previously reported NUP98-LEDGF transcript [2]
encodes a protein fusing the amino terminus of the
NUP98 gene containing 28 of the 38 FG repeats with
exon 6 onwards of p52/75. FG repeats in NUP98 fusion
proteins have been shown to act as transactivation do-
mains which recruit CBP/p300 [8,12]. The minimum
number of FG repeats which are important for the trans-
forming properties of NUP98 fusion proteins has not yet
been defined. The fusion in our patient contains 23 FG
repeats from NUP98. Interestingly, just after the break-
point LEDGF exon 2 codes for an additional FG residue.
It is unknown whether this residue is important for the
function of the NUP98-LEDGF fusion protein.
The LEDGF gene codes for 2 transcriptional co-activa-
tors, p75 (LEDGF: Lens Epithelium Derived Growth
Factor) and p52 which have different 3' ends generated
by alternative splicing [15,13]. Both NUP98-p52 and
NUP98-p75 fusion mRNAs were seen in our patient at
presentation and relapse (data not shown) as well as in
the previously characterised t(9;11) patient [2]. It re-
mains to be determined whether one transcript is more
important in the leukemogenic process.
p52 and p75 both contain a PWWP domain at their ami-
no terminus [14]. PWWP is the core motif of a 70 amino
acid domain found in a variety of nuclear proteins [14].
The PWWP domain was lost in the NUP98-LEDGF fu-
sion described by Ahuja et al [2] and disrupted in the fu-
sion described here. Interestingly, the PWWP domain is
also found in NSD1, the most recently identified NUP98
partner gene and is absent in the NUP98-NSD1 fusion
transcript [10].
The three AML patients with the t(9;11)(p22;p15) vary in
their clinical picture (Table 1). At this stage, it is too early
to determine which clinicopathological features are a
hallmark of this translocation, especially as it is not clear
as to whether the first patient's translocation has a simi-
lar molecular basis to the other two. Patients 2 and 3
have a more mature myeloid phenotype than that seen in
patient 1. All three presented with the t(9;11)(p22;p15) as
their sole cytogenetic abnormality. At relapse, the leuke-
mic cells of both patients 2 and 3 had the same karyotype
as at presentation whereas the relapse karyotype of pa-
tient 1 no longer showed the translocation.
Some NUP98 translocations are associated with second-
ary leukemias that occur after treatment with topoi-
somerase II inhibitors [3–8,15]. The patient in this
report had not received chemotherapy prior to her dis-
ease and prior chemotherapy was not mentioned in ei-
ther of the other two case reports [1,2]. It seems that
t(9;11)(p22;p15) is preferentially associated with de-
novo AML rather than therapy related AML.
Conclusions
Our results show that fusion of the NUP98 and LEDGF
genes is a recurrent translocation in AML. Further study
is required to determine how this fusion gene promotes
leukemia.
Table 1: Clinical features, immunophenotype of patients with the t(9;11)(p22p15).
Patient Sex/Age WCC ×  109/L Diagnosis Survival (months) Immunophenotype (where less than 50% of cells are involved, 
the fraction is given).
Reference
1 F/20 63.8 AML M1 3 CD33 (50%), CD13 (10%) negative for CD11b, CD 14 HLA DR, 
CD34 CD 19, CD22, negative for CD 10 negative for CD2, 
CD5, CD7, CD41, CD61, CD62 Nuclear TdTnegative. Blasts 
were positive for PAS, Sudan black and myeloperoxidase and 
negative for non-specific esterase.
1
2 M/52 50.5 AML M1 9 CD33, CD13, CD11c, CD15 (15%), CD36 HLA-DR, negative 
for CD34 negative for CD10, CD19, CD20, CD56 CD4 (20%), 
negative for CD5, CD7 Blasts were positive for myeloperoxi-
dase with a subset positive for non-specific esterase.
2
3 F/60 1.5 AML M2 54 CD33, CD13, CD11b (14%) negative for CD34, HLA-DR nega-
tive for CD10, CD19, CD20 negative for CD2, CD3, CD5
This report
Details of the three patients discussed in this study are presented. All features except for survival are at presentation. Where surface markers are 
positive in less than 50% of cells, the proportion of positive cells is indicated in parentheses.BMC Genetics 2001, 2:20 http://www.biomedcentral.com/1471-2156/2/20
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Materials and methods
RT-PCR analysis
RNA was obtained from bone marrow or peripheral
blood mononuclear cells using Trizol (Invitrogen). RNA
was reverse transcribed using Superscript II (Invitro-
gen). 3' RACE was performed using the 3' RACE System
for Rapid Amplification of cDNA Ends (Invitrogen). The
manufacturer's protocol for "First Strand cDNA Synthe-
sis of Transcripts with High GC Content" was used. RT-
PCR to amplify the NUP98-LEDGF fusion was per-
formed using a NUP98 forward primer from exon 8
(N988F 5'ACCAGCCTCTTCAGCAAACCATTTG3') and a
LEDGF reverse primer from exon 6 (L826R
5'AACAGATGCTGTTGCTGTTGTCAC3'). NUP98 exons
are numbered according to Genbank AB040538 and
LEDGF exons are numbered according to reference 16.
Subsequently, the N988F primer was used in combina-
tion with either a p52 reverse primer
(5'CTTCATCTCTTGTTTGCTCCACTTG3') or a p75 re-
verse primer (5'CTCAGCATGTATCCTTTGAAGTCG3')
to amplify NUP98-p52 and NUP98-p75 fusion tran-
scripts respectively. The PBGD transcript was amplified
using primers specific for the housekeeping isoform,
(5'CTTTCCAAGCGGAGCCATGTCTGG3' and
5'CATGAGGGTTTTCCCGCTTGCAGA3'). PCR was per-
formed using HotStarTaq (Qiagen) according to the
manufacturer's instructions with an initial incubation at
95°C for 15 minutes followed by 35 cycles of 96°C for 30
seconds, 65°C for 45 seconds and 72°C for 1 minute.
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